Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system
Abstract Oncolytic virotherapy has the disadvantage of being unsuitable for systemic delivery due to immune elimination. Liposomal encapsulation is well-recognized to reduce immune elimination and enhance the stability of drugs in the bloodstream. In the present study, the potential of liposome-enca...
Enregistré dans:
Auteurs principaux: | Katsuyuki Aoyama, Shinji Kuroda, Toshiaki Morihiro, Nobuhiko Kanaya, Tetsushi Kubota, Yoshihiko Kakiuchi, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa, Toshiyoshi Fujiwara |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/20760a868f17433c8d8ecd81b0ee0a17 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma
par: Eonju Oh, et autres
Publié: (2018) -
Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy
par: Huiya Huang, et autres
Publié: (2019) -
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses.
par: Anna Kanerva, et autres
Publié: (2008) -
A potential bat adenovirus-based oncolytic virus targeting canine cancers
par: Hiromichi Matsugo, et autres
Publié: (2021) -
Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
par: Elisa Callegari, et autres
Publié: (2013)